Respiratory Syncytial Virus News and Research

RSS

Preparing for the respiratory virus season: A guide for families

As respiratory virus season begins, pediatric experts are preparing for an expected rise in cases of Respiratory Syncytial Virus (RSV), which can cause cold-like symptoms in most people but serious illness in infants and older adults.

17 Nov 2025

AI and protein language models can accelerate the design of antiviral antibodies

Artificial intelligence (AI) and "protein language" models can speed the design of monoclonal antibodies that prevent or reduce the severity of potentially life-threatening viral infections, according to a multi-institutional study led by researchers at Vanderbilt University Medical Center.

5 Nov 2025

COVID-19, RSV, and flu vaccines remain safe and effective

The systematic review provides crucial insights into the efficacy and safety of respiratory virus vaccines, supporting evidence-based immunization practices.

3 Nov 2025

Study reveals impact of viral combinations on infant respiratory illness severity

A new study led by researchers at National Jewish Health has revealed that, while a wide range of viruses can cause lower respiratory tract illnesses (LRIs) in infants, certain viruses and viral combinations dramatically increase the risk of severe disease.

24 Oct 2025

A parent's guide to manage pediatric respiratory illnesses during the virus season

As we head deeper into fall and toward the holiday season, your little one may start to exhibit symptoms like a runny nose, cough, or fever.

24 Oct 2025

Research opens new avenues for treating asthma and other inflammatory diseases

For decades, scientists have thought they understood the biochemical machinery that causes asthma-inflammation in the lungs that constricts airways and makes it hard to breathe.

23 Oct 2025

Despite the hoopla, vaccines should be in reach this cough-and-cold season

For people whose autumn agenda includes getting vaccinated against respiratory diseases — covid, flu, and, for some, RSV — this year may be surprisingly routine.

22 Oct 2025

HEPA purifiers do not fully reduce classroom viral exposure

In a secondary analysis of a study of 200 classrooms, Mass General Brigham researchers found respiratory viral exposures were still high in those with HEPA purifiers, suggesting additional interventions are needed.

10 Oct 2025

RSV vaccines protect two most-at-risk groups from severe illness

The review demonstrates that vaccines for respiratory syncytial virus (RSV) are both safe and effective in protecting groups who are most at risk for serious illness, including older adults and infants.

29 Sep 2025

Nirsevimab sharply cuts RSV hospitalizations in U.S. infants during the 2024–2025 season

In a nationwide EHR cohort of over 400,000 U.S. infants during the 2024–2025 RSV season, nirsevimab use was linked to a 77% lower risk of RSV-related hospitalization. The study also found reduced ICU admissions and intubations, supporting broad seasonal protection in routine care.

28 Sep 2025

$Kennedy’s take on vaccine science fractures cohesive national public health strategies$

Kennedy’s take on vaccine science fractures cohesive national public health strategies

Health and Human Services Secretary Robert F. Kennedy Jr. has had a busy few months. He fired the director of the Centers for Disease Control and Prevention, purged the agency's vaccine advisory committee, and included among the group's new members appointees who espouse anti-vaccine views.

19 Sep 2025

Soap shortages undermine global hand hygiene efforts

A lack of soap is the most often reported barrier to effective hand hygiene-key to curbing the spread of infection-in shared community spaces, such as households, schools, and public places, finds a systematic review of the available research, published in the open access journal BMJ Global Health.

17 Sep 2025

RSV vaccine slashes hospitalizations in older adults in real-world trial

A large, real-world randomized trial in Denmark found that the RSVpreF vaccine reduced RSV-related hospitalizations in adults aged 60 and over by over 80%. The vaccine also showed protection against broader respiratory illness with a favorable safety profile.

15 Sep 2025